All data are based on the daily closing price as of April 28, 2025
c

Chugai Pharmaceutical

4519.TSE
55.89 USD
-1.84
-3.19%

Overview

Last close
55.89 usd
Market cap
91.96B usd
52 week high
59.92 usd
52 week low
29.51 usd
Target price
56.67 usd

Valuation

P/E
33.2222
Forward P/E
30.2115
Price/Sales
11.0719
Price/Book Value
7.1387
Enterprise Value
88.31B usd
EV/Revenue
10.3677
EV/EBITDA
21.8917

Key financials

Revenue TTM
8.52B usd
Gross Profit TTM
6.05B usd
EBITDA TTM
4.22B usd
Earnings per Share
1.74 usd
Dividend
0.68 usd
Total assets
14.13B usd
Net debt
-3.46B usd

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
  • Symbol
    4519.TSE
  • Exchange
    TSE
  • Isin
    JP3519400000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Dr. Osamu Okuda
  • Headquarter
    Chuo
  • Web site
    https://www.chugai-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top